New Publication Elaborates on TB4’s Effects on Dry Eye Syndrome and Other Potential Ophthalmic Disorders

ROCKVILLE, Md., Aug. 12, 2015 /PRNewswire

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced a new peer-reviewed publication describing Thymosin beta 4’s (TB4) effects on dry eye syndrome and its potential value for the treatment of other ophthalmic disorders. The authors of the paper explained how TB4’s reported mechanisms of action help alleviate the signs and symptoms of dry eye by promoting stem cell recruitment and cell migration, reducing inflammation and apoptosis, enhancing cytoprotection, and promoting gene expression.